Kroll, François
Dimitriadis, Athanasios
Campbell, Tracy
Darwent, Lee
Collinge, John
Mead, Simon
Vire, Emmanuelle
Funding for this research was provided by:
Leonard Wolfson PhD Programme in Neurodegeneration
Onassis Foundation (Scholarship ID: F ZQ 022-1/2020-2021)
UK Medical Research Council
National Institute of Health Research (NIHR) Biomedical Research Centre at UCL Hospitals NHS Foundation Trust
Article History
Received: 17 February 2022
Accepted: 5 May 2022
First Online: 18 May 2022
Competing interests
: Prof. Collinge is a director and shareholder of D-Gen Limited (London), an academic spinout company working in the field of prion disease diagnosis, decontamination and therapeutics. François Kroll owns stocks in Oxford Nanopore Technologies and Pacific Biosciences. All other authors declare no competing interests.